Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Cellectar Biosciences Inc CLRB

Healthcare Biotechnology

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).

NDAQ:CLRB - Post by User

Cellectar Biosciences Inc

Bullboard Posts

Post by aeeon Jan 21, 2019 2:50pm

216 Views

Post# 29260876

FDA Import Alert

For the record, the FDA Import Alert stopping CLR131 imports from CPDC can be found at

https://www.accessdata.fda.gov/cms_ia/importalert_189.html

CLRB has a exception for hematology studies, but not yet for the clinical trials.

Bullboard Posts

As AI expands, where can investors look for strong growth?

As AI expands, where can investors look for strong growth?

One of the strongest contenders to lead Canada’s cannabis market

One of the strongest contenders to lead Canada’s cannabis market

Fobi AI could address a market in the trillions: Why it's time to buy

Fobi AI could address a market in the trillions: Why it's time to buy

Critical raw materials pioneer drives Europe’s clean energy transition

Critical raw materials pioneer drives Europe’s clean energy transition

This profitable gold stock is on its way up

This profitable gold stock is on its way up